A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation
Latest Information Update: 23 Feb 2026
At a glance
- Drugs Ribociclib (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PARFENOPA
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 20 Feb 2026 Planned End Date changed from 30 Oct 2027 to 31 Dec 2027.
- 20 Feb 2026 Planned primary completion date changed from 30 Oct 2027 to 31 Dec 2027.
- 20 Feb 2026 Status changed from recruiting to active, no longer recruiting.